Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026

Phase 2BersiporocinPositive

AI Analysis

Summary

Daewoong Pharmaceutical presented baseline data from a global Phase 2 trial of Bersiporocin, a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis, enrolling 104 patients across the US and South Korea with top-line results anticipated in H1 2027.

Clinical Trial Data

Phase

Phase 2

Patients

104

Outcome Details

Baseline characteristics presented; top-line data expected in H1 2027

Importance:5/10

Sentiment:

0.30

IPFPhase 2Clinical TrialFirst-in-classPRS inhibitorConference Presentation

Related Companies

$INTI $GBCMD $OPTN $TRAX

Read the original article

Published by PR Newswire Pharma on September 24, 2026 7:00 AM

Read Original